Johnson & Johnson is betting that it will avoid having to pay a hefty award to the state of Oklahoma in choosing to go to trial rather than reaching a settlement in opioid litigation. If it wins a favorable ruling, it could also be in a better position to defend itself against claims in massive multidistrict litigation pending in Ohio.
In 28 May opening statements in the Oklahoma bench trial, attorneys for the state contended that J&J's Janssen Pharmaceuticals...





